{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:03:50Z","timestamp":1793516630611,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271388"],"award-info":[{"award-number":["32271388"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014857","name":"National Natural Science Foundation of China-Guangdong Joint Fund","doi-asserted-by":"publisher","award":["2021A1515010408"],"award-info":[{"award-number":["2021A1515010408"]}],"id":[{"id":"10.13039\/501100014857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.actbio.2023.10.038","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T02:28:07Z","timestamp":1699583287000},"page":"281-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"174","author":[{"given":"Xuan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangman","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongfei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunbao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-4138","authenticated-orcid":false,"given":"Mingqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5243-042X","authenticated-orcid":false,"given":"Dan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0001","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.actbio.2023.10.038_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.963630","article-title":"Editorial: Chronic liver disease: new targets and new mechanisms","volume":"9","author":"Ye","year":"2022","journal-title":"Front. Mol. Biosci"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.actbio.2023.10.038_bib0004","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am. J. Transplant."},{"issue":"48","key":"10.1016\/j.actbio.2023.10.038_bib0005","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1002\/adfm.201503115","article-title":"Rational design of polymeric hybrid micelles with highly tunable properties to co-deliver MicroRNA-34a and vismodegib for melanoma therapy","volume":"25","author":"Li","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.actbio.2023.10.038_bib0006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2017.01.008","article-title":"Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy","volume":"122","author":"Wang","year":"2017","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10555-017-9717-6","article-title":"RNA interference-based therapy and its delivery systems","volume":"37","author":"Chen","year":"2018","journal-title":"Cancer Metast. Rev."},{"key":"10.1016\/j.actbio.2023.10.038_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.actbio.2023.10.038_bib0009","doi-asserted-by":"crossref","first-page":"e13243","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med"},{"issue":"7659","key":"10.1016\/j.actbio.2023.10.038_bib0010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.actbio.2023.10.038_bib0011","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0012","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1038\/s41467-019-10562-w","article-title":"Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes","volume":"10","author":"Qiu","year":"2019","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.actbio.2023.10.038_bib0013","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"14","key":"10.1016\/j.actbio.2023.10.038_bib0014","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1002\/anie.201208077","article-title":"Systemic delivery of microRNA-34a for cancer stem cell therapy","volume":"52","author":"Shi","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"issue":"11","key":"10.1016\/j.actbio.2023.10.038_bib0015","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.actbio.2023.10.038_bib0016","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1478-3231.2006.01342.x","article-title":"Role of Kupffer cells in host defense and liver disease","volume":"26","author":"Bilzer","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.actbio.2023.10.038_bib0017","doi-asserted-by":"crossref","first-page":"114238","DOI":"10.1016\/j.addr.2022.114238","article-title":"Why nanoparticles prefer liver macrophage cell uptake in vivo","volume":"185","author":"Ngo","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2023.10.038_bib0018","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","article-title":"Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Tar."},{"key":"10.1016\/j.actbio.2023.10.038_bib0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting \u2014 strategies and applications","volume":"203","author":"D'Souza","year":"2015","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.actbio.2023.10.038_bib0021","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","article-title":"Liver as a target for oligonucleotide therapeutics","volume":"59","author":"Sehgal","year":"2013","journal-title":"J. Hepatol."},{"issue":"25","key":"10.1016\/j.actbio.2023.10.038_bib0022","doi-asserted-by":"crossref","first-page":"16259","DOI":"10.1021\/acsomega.1c01755","article-title":"Liver-targeted delivery of oligonucleotides with N-Acetylgalactosamine conjugation","volume":"6","author":"Cui","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.actbio.2023.10.038_bib0023","doi-asserted-by":"crossref","first-page":"114236","DOI":"10.1016\/j.addr.2022.114236","article-title":"Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics","volume":"184","author":"Vervaeke","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"15","key":"10.1016\/j.actbio.2023.10.038_bib0024","doi-asserted-by":"crossref","first-page":"1900605","DOI":"10.1002\/advs.201900605","article-title":"Engineering cell membrane-based nanotherapeutics to target inflammation","volume":"6","author":"Yan","year":"2019","journal-title":"Adv. Sci."},{"issue":"12","key":"10.1016\/j.actbio.2023.10.038_bib0025","doi-asserted-by":"crossref","first-page":"17273","DOI":"10.1021\/acsnano.0c07298","article-title":"Stability of lipid coatings on nanoparticle-decorated surfaces","volume":"14","author":"Patel","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2023.10.038_bib0026","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jconrel.2020.09.012","article-title":"Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy","volume":"327","author":"Dash","year":"2020","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.actbio.2023.10.038_bib0027","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","article-title":"Comprehensive structure\u2013activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes","volume":"59","author":"Prakash","year":"2016","journal-title":"J. Med. Chem."},{"issue":"49","key":"10.1016\/j.actbio.2023.10.038_bib0028","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene Silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"29","key":"10.1016\/j.actbio.2023.10.038_bib0029","article-title":"Bioinspired diselenide-bridged mesoporous silica nanoparticles for dual-responsive protein delivery","volume":"30","author":"Shao","year":"2018","journal-title":"Adv. Mater."},{"issue":"50","key":"10.1016\/j.actbio.2023.10.038_bib0030","article-title":"Biomimetic diselenide-bridged mesoporous organosilica nanoparticles as an X-ray-responsive biodegradable carrier for chemo-immunotherapy","volume":"32","author":"Shao","year":"2020","journal-title":"Adv. Mater."},{"issue":"8","key":"10.1016\/j.actbio.2023.10.038_bib0031","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7150\/thno.11852","article-title":"Cell or cell membrane-based drug delivery systems","volume":"5","author":"Tan","year":"2015","journal-title":"Theranostics"},{"issue":"23","key":"10.1016\/j.actbio.2023.10.038_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143812","article-title":"microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production","volume":"5","author":"Dong","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.actbio.2023.10.038_bib0033","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1021\/acsnano.2c02084","article-title":"Quantification of available ligand density on the surface of targeted liposomal nanomedicines at the single-particle level","volume":"16","author":"Chen","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2023.10.038_bib0034","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2019.05.010","article-title":"Ligand density on nanoparticles: a parameter with critical impact on nanomedicine","volume":"143","author":"Alkilany","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.actbio.2023.10.038_bib0035","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1021\/acsnano.1c08277","article-title":"A single-molecule view at nanoparticle targeting selectivity: correlating ligand functionality and cell receptor density","volume":"16","author":"Woythe","year":"2022","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0036","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1021\/acsami.8b18843","article-title":"Ligand density and linker length are critical factors for multivalent nanoparticle\u2013receptor interactions","volume":"11","author":"Abstiens","year":"2019","journal-title":"ACS Appl. Mater. Inter."},{"key":"10.1016\/j.actbio.2023.10.038_bib0037","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.biomaterials.2015.02.001","article-title":"Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery","volume":"52","author":"Chen","year":"2015","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.actbio.2023.10.038_bib0038","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1021\/acsnano.9b01383","article-title":"Elimination pathways of nanoparticles","volume":"13","author":"Poon","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0039","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s40820-019-0330-9","article-title":"Cell membrane coating technology: a promising strategy for biomedical applications","volume":"11","author":"Liu","year":"2019","journal-title":"Nano-micro Lett"},{"issue":"1, Supplement","key":"10.1016\/j.actbio.2023.10.038_bib0040","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"issue":"Supplement_1","key":"10.1016\/j.actbio.2023.10.038_bib0041","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.2462","article-title":"Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis of prospective studies","volume":"42","author":"Bisaccia","year":"2021","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.actbio.2023.10.038_bib0042","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1073\/pnas.0904560106","article-title":"Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels","volume":"106","author":"Steinberg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.actbio.2023.10.038_bib0043","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153640","article-title":"Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player","volume":"131","author":"Rodrigues","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.actbio.2023.10.038_bib0044","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.blre.2014.10.002","article-title":"Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?","volume":"29","author":"Hugenholtz","year":"2015","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.actbio.2023.10.038_bib0045","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2165\/00003495-199039060-00002","article-title":"Current therapy of chronic liver disease","volume":"39","author":"Stavinoha","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.actbio.2023.10.038_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100063","article-title":"siRNA therapeutics and its challenges: recent advances in effective delivery for cancer therapy","volume":"7","author":"Paul","year":"2022","journal-title":"OpenNano"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0047","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymthe.2017.08.019","article-title":"Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression","volume":"26","author":"Willoughby","year":"2018","journal-title":"Mol. Ther."},{"issue":"43","key":"10.1016\/j.actbio.2023.10.038_bib0048","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202004397","article-title":"Improving cancer immunotherapy by cell membrane-camouflaged nanoparticles","volume":"30","author":"Zeng","year":"2020","journal-title":"Adv. Funct. Mater."},{"issue":"3","key":"10.1016\/j.actbio.2023.10.038_bib0049","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1021\/acs.chemrev.0c00779","article-title":"The use of alternative strategies for enhanced nanoparticle delivery to solid tumors","volume":"121","author":"Izci","year":"2021","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.actbio.2023.10.038_bib0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio.2297","article-title":"Selective in vivo metabolic cell-labeling-mediated cancer targeting","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"11","key":"10.1016\/j.actbio.2023.10.038_bib0051","doi-asserted-by":"crossref","first-page":"10724","DOI":"10.1021\/acsnano.7b04955","article-title":"Biomimetic magnetosomes as versatile artificial antigen-presenting cells to potentiate T-cell-based anticancer therapy","volume":"11","author":"Zhang","year":"2017","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.actbio.2023.10.038_bib0052","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1074\/jbc.RA119.011122","article-title":"Membrane fluidity adjusts the insertion of the transacylase PlsX to regulate phospholipid biosynthesis in Gram-positive bacteria","volume":"295","author":"Sastre","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.actbio.2023.10.038_bib0053","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154-155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2023.10.038_bib0054","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle\u2013liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.038_bib0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1517\/17425247.5.1.11","article-title":"Liposome-nucleic acid immunotherapeutics","volume":"5","author":"Dow","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"issue":"21","key":"10.1016\/j.actbio.2023.10.038_bib0056","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100460","article-title":"Genetically engineered cellular membrane vesicles as tailorable shells for therapeutics","volume":"8","author":"Ren","year":"2021","journal-title":"Adv. Sci."},{"issue":"8","key":"10.1016\/j.actbio.2023.10.038_bib0057","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202200289","article-title":"Macrophage cell membrane-cloaked nanoplatforms for biomedical applications","volume":"6","author":"Lopes","year":"2022","journal-title":"Small Methods"},{"issue":"11","key":"10.1016\/j.actbio.2023.10.038_bib0058","doi-asserted-by":"crossref","first-page":"17080","DOI":"10.1021\/acsnano.1c03800","article-title":"Cell membrane-coated mimics: a methodological approach for fabrication, characterization for therapeutic applications, and challenges for clinical translation","volume":"15","author":"Chugh","year":"2021","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.actbio.2023.10.038_bib0059","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1418","article-title":"Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia","volume":"8","author":"Hu","year":"2022","journal-title":"Sci. Adv."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123006463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123006463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:16:30Z","timestamp":1761675390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706123006463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":59,"alternative-id":["S1742706123006463"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2023.10.038","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2023.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}